Combination BrECADD Is Significantly More Effective Than BEACOPP for Classical Hodgkin Lymphoma, Study Finds
Although advancements in the treatment of classical Hodgkin lymphoma have increased the 5-year relative survival rate of patients with the disease to nearly 90%, dose-intensified treatment strategies may increase the risk for acute and long-term toxicities.
The German Hodgkin Study Group (GHSG) HD21 trial compared the BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) chemotherapy regimen with the current standard-of-care BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) regimen in a positron-emission tomography (PET)-adapted approach in patients with advanced-stage classical Hodgkin lymphoma. The final analysis of the trial found BrECADD to be significantly more effective than a regimen of BEACOPP. The therapeutic combination was associated with an unprecedentedly high 4-year progression-free survival, reducing the risk of disease progression, relapse, or death by one-third. In combination with an abbreviated therapy duration of 3 months for the majority of patients and a favorable tolerability, treatment with PET-guided BrECADD sets a new benchmark for the treatment of late-stage classical Hodgkin lymphoma, concluded the study authors. The study was presented during the 2024 ASCO Annual Meeting by Peter Borchmann, MD, and colleagues (Abstract LBA7000).
Study Methodology
The intention-to-treat cohort for this analysis consisted of 1,482 adult patients with advanced-stage classical Hodgkin lymphoma. The median age of the cohort was 31.1 years and 44% were female. Patients were randomly assigned to receive an individualized four or six cycles of either BEACOPP or BrECADD guided by PET after two cycles (PET2). The co-primary endpoints included treatment-related morbidity and noninferiority in terms of progression-free survival. Testing for superiority was planned with mature follow-up of 4 years. An adjusted alpha level of 0.047 was required to cross the efficacy boundary for superiority.
Results
Patients were randomly assigned in a 1:1 ratio; 742 received BrECADD and 740 received BEACOPP. The researchers found that PET2 was negative in 424 (57.5%) and 426 (58.2%) patients receiving BrECADD and BEACOPP, respectively, after four treatment cycles.
With a median follow-up of 48 months, 4-year progression-free survival was 94.3% in those receiving BrECADD (95% confidence interval [CI] = 92.6%–96.1%) and 90.9% in those receiving BEACOPP (95% CI = 88.7%–93.1%; hazard ratio = 0.66, 95% CI 0.45–0.97, P = .035). The progression-free survival benefit of BrECADD was driven by a reduction in early treatment failures, such as primary progression within 3 months (5 vs 15) or early relapse between months 3 and 12 (11 vs 23), and was observed across all investigated subgroups.
PET2-negative patients in the BrECADD group showed a 4-year progression-free survival rate of 96.5%. Four-year overall survival was 98.5% for those in the BrECADD group and 98.2% for those in the BEACOPP group. Analyses of gonadal function demonstrated significantly higher follicle-stimulating hormone recovery rates after 1 year in both men (67% vs 24%) and women (89% vs 68%), with higher birthrates in the BrECADD group (n = 60 vs n = 43).
Conclusion
“BrECADD is significantly more effective than BEACOPP and is associated with an unprecedentedly high 4-year progression-free survival, reducing the risk of progression, relapse, or death by a third. Together with an abbreviated treatment duration of only 3 months for the majority of patients and a favorable tolerability, treatment with PET2-individualized BrECADD sets a new benchmark for the treatment of adult patients with advanced-stage classical Hodgkin lymphoma,” concluded the study authors.
Disclosure: Funding for this study was provided by Takeda Oncology. For full disclosures of the study authors, visit coi.asco.org.